Table 6.
In Situ Detection of LAM and PGL-I in the Lesional Skin of MB and PB Patients Undergoing RR and ENL in the Course of the Disease
| Patients with reactions | Localization | Positive staining pattern | |
|---|---|---|---|
| LAM* | PGL-I† | ||
| RR (n = 4; BI 4+) | Granuloma | 4 /4 | 0 /4 |
| Scattered cells | 0 /4 | 4 /4 | |
| RR (n = 4; BI 0–1+) | Granuloma | 0 /4 | 0 /4 |
| Scattered cells | 0 /4 | 4 /4 | |
| ENL (n = 1; BI 5+) | Granuloma | 1 /1 | 1 /1 |
| Scattered cells | 0 /1 | 1 /1 | |
| ENL (n = 5; BI 0–2+) | Granuloma | 4 /5 | 3‡ /5 |
| Scattered cells | 1 /5 | 4 /5 |
In situ presence of LAM and PGL-I was determined by immunohistochemical analysis using MAbs F 30-5 and DZ-1, respectively. RR, reversal reaction; ENL, erythema nodosum leprosum.
*Granular staining pattern.
†Staining pattern was as clumps.
‡In two lesions the staining was weak.